marijuana-Dartmouth-Hitchcock Medical Center-schizophrenia-cannabis use disorder

This identifier refers to a clinical research protocol (NCT01964404) led by investigators at Dartmouth-Hitchcock Medical Center to evaluate the self-medication hypothesis in patients with schizophrenia and comorbid cannabis use disorder. The study investigates the pharmacological effects of two cannabinoid agonists: smoked marijuana (cannabis) and oral dronabinol (synthetic delta-9-tetrahydrocannabinol). Both substances act primarily as agonists at the CB1 and CB2 receptors. The trial utilizes a double-dummy, placebo-controlled design to determine if low-dose cannabinoid administration can normalize dysregulated brain reward circuitry, as measured by functional MRI, and potentially improve cognitive and psychiatric outcomes in this patient population.

Other names

MarijuanaCannabisDronabinolTHCDelta-9-tetrahydrocannabinolDelta9-tetrahydrocannabinolDelta 9-tetrahydrocannabinol